Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
Primary Purpose
Alpha Mannosidosis
Status
Unknown status
Phase
Phase 2
Locations
Denmark
Study Type
Interventional
Intervention
Lamazym
Sponsored by
About this trial
This is an interventional treatment trial for Alpha Mannosidosis
Eligibility Criteria
Inclusion Criteria:
- The patient must have a confirmed diagnosis of alpha-Mannosidosis as defined by alpha-mannosidase activity < 10% of normal activity in blood leukocytes
- The patient must have an age at the time of screening ≥ 5 year and ≤ 21 years
- The patient must have physical ability to perform 6-minutes walk test (6MWT), 3 minute-stair climb test (3MSCT) and pulmonary lung function test (spirometry, body plethysmography).
- The patient must have the ability to mentally cooperate in the cognitive and motor function tests
- The patient must have the ability to hear and follow a request. Hearing aids can be worn.
- Patient or patient's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject)
- The patient and his/her guardian(s) must have the ability to comply with the protocol
Exclusion Criteria:
- The patient cannot walk without support.
- Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-Mannosidosis
- History of bone marrow transplantation
- Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial
- Presence of an ECHO with abnormalities within half a year that, in the opinion of the Investigator, would preclude participation in the trial
- Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial
- Pregnancy
- Psychosis within the last 3 months
Sites / Locations
- Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Lamazym 25
Lamazym 50
Arm Description
25 U/kg
50 U/kg
Outcomes
Primary Outcome Measures
Reduction of Oligosaccharides in urine
Efficacy endpoint evaluation as change from baseline
Secondary Outcome Measures
Reduction of Oligosaccharides in serum
Efficacy endpoint evaluation as change from baseline
Reduction of Oligosaccharides in CSF
Efficacy endpoint evaluation as change from baseline
The distance walked in 6 minutes
Efficacy endpoint evaluation as change from baseline
The number of steps climbed in 3 minutes
Efficacy endpoint evaluation as change from baseline
Pulmonary Function
Efficacy endpoint evaluation as change from baseline
Adverse events
Safety endpoint assessed weekly throughout the trial
Development of clinically significant changes in vital signs and change in physical examination
Safety endpoint assessed weekly throughout the trial
Development of clinically significant changes in the clinical laboratory parameters (hematology, biochemistry and urinalysis)
Safety endpoint assessed every 4th week throughout the trial
Development of rhLAMAN antibodies and neutralizing/inhibitory antibodies
Safety endpoint assessed every other week throughout the trial
Full Information
NCT ID
NCT01285700
First Posted
January 25, 2011
Last Updated
September 25, 2012
Sponsor
Zymenex A/S
Collaborators
European Commission
1. Study Identification
Unique Protocol Identification Number
NCT01285700
Brief Title
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
Official Title
A Single Center, Randomized, Open-label, Multiple-dose Study of the Efficacy and Long-term Safety of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2012
Overall Recruitment Status
Unknown status
Study Start Date
January 2011 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
November 2012 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zymenex A/S
Collaborators
European Commission
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a single-center, open-label, multiple-dose study of the efficacy and long-term safety of Lamazym for the treatment of patients with alpha-mannosidosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alpha Mannosidosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lamazym 25
Arm Type
Active Comparator
Arm Description
25 U/kg
Arm Title
Lamazym 50
Arm Type
Active Comparator
Arm Description
50 U/kg
Intervention Type
Drug
Intervention Name(s)
Lamazym
Other Intervention Name(s)
rhLAMAN
Intervention Description
ERT, infusion weekly
Primary Outcome Measure Information:
Title
Reduction of Oligosaccharides in urine
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Secondary Outcome Measure Information:
Title
Reduction of Oligosaccharides in serum
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Title
Reduction of Oligosaccharides in CSF
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Title
The distance walked in 6 minutes
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Title
The number of steps climbed in 3 minutes
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Title
Pulmonary Function
Description
Efficacy endpoint evaluation as change from baseline
Time Frame
3 months (interim evaluation) + 6 months
Title
Adverse events
Description
Safety endpoint assessed weekly throughout the trial
Time Frame
1 week
Title
Development of clinically significant changes in vital signs and change in physical examination
Description
Safety endpoint assessed weekly throughout the trial
Time Frame
1 week
Title
Development of clinically significant changes in the clinical laboratory parameters (hematology, biochemistry and urinalysis)
Description
Safety endpoint assessed every 4th week throughout the trial
Time Frame
4 weeks
Title
Development of rhLAMAN antibodies and neutralizing/inhibitory antibodies
Description
Safety endpoint assessed every other week throughout the trial
Time Frame
2 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patient must have a confirmed diagnosis of alpha-Mannosidosis as defined by alpha-mannosidase activity < 10% of normal activity in blood leukocytes
The patient must have an age at the time of screening ≥ 5 year and ≤ 21 years
The patient must have physical ability to perform 6-minutes walk test (6MWT), 3 minute-stair climb test (3MSCT) and pulmonary lung function test (spirometry, body plethysmography).
The patient must have the ability to mentally cooperate in the cognitive and motor function tests
The patient must have the ability to hear and follow a request. Hearing aids can be worn.
Patient or patient's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject)
The patient and his/her guardian(s) must have the ability to comply with the protocol
Exclusion Criteria:
The patient cannot walk without support.
Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-Mannosidosis
History of bone marrow transplantation
Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial
Presence of an ECHO with abnormalities within half a year that, in the opinion of the Investigator, would preclude participation in the trial
Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial
Pregnancy
Psychosis within the last 3 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Allan M. Lund, MD
Organizational Affiliation
Department of Clinical Genetics, Juliane Marie Centre, Region Hovedstaden, Copenhagen University hospital, Denmark
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jens Fogh
Organizational Affiliation
Zymenex A/S
Official's Role
Study Chair
Facility Information:
Facility Name
Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
We'll reach out to this number within 24 hrs